{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T10:19:46Z","timestamp":1784715586483,"version":"3.55.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2020R1G1A1099822"],"award-info":[{"award-number":["2020R1G1A1099822"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bio & Medical Technology Development Program of the NRF","award":["2017M3A9B6061825"],"award-info":[{"award-number":["2017M3A9B6061825"]}]},{"name":"Ministry of Science and ICR"},{"name":"Health Technology R&D Project through the Korea Health Industry Development Institute"},{"name":"Ministry of Health & Welfare, Republic of Korea","award":["HI20C1586"],"award-info":[{"award-number":["HI20C1586"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04005-3","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T14:00:40Z","timestamp":1742392840000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Antitumor effects of immunotherapy combined with BRAF and MEK inhibitors in BRAF V600E metastatic colorectal cancer"],"prefix":"10.1007","volume":"74","author":[{"given":"Eunyoung","family":"Tak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye-In","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy Sinyoung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyuyoung","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwan","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung-don","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Sang","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Kyung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9766-1531","authenticated-orcid":false,"given":"Jeong Eun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"4005_CR1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1053\/j.gastro.2020.02.068","volume":"159","author":"M Arnold","year":"2020","unstructured":"Arnold M, Abnet CC, Neale RE, Vignat J, Giovannucci EL, McGlynn KA, Bray F (2020) Global burden of 5 major types of gastrointestinal cancer. Gastroenterology 159:335\u201349.e15. https:\/\/doi.org\/10.1053\/j.gastro.2020.02.068","journal-title":"Gastroenterology"},{"key":"4005_CR2","doi-asserted-by":"publisher","first-page":"335","DOI":"10.4143\/crt.2020.206","volume":"52","author":"S Hong","year":"2020","unstructured":"Hong S, Won YJ, Park YR, Jung KW, Kong HJ, Lee ES (2020) Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2017. Cancer Res Treat 52:335\u2013350. https:\/\/doi.org\/10.4143\/crt.2020.206","journal-title":"Cancer Res Treat"},{"key":"4005_CR3","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1016\/j.clcc.2017.10.006","volume":"17","author":"H Kayhanian","year":"2018","unstructured":"Kayhanian H, Goode E, Sclafani F et al (2018) Treatment and survival outcome of BRAF-mutated metastatic colorectal cancer: a retrospective matched case-control study. Clin Colorectal Cancer 17:e69\u2013e76. https:\/\/doi.org\/10.1016\/j.clcc.2017.10.006","journal-title":"Clin Colorectal Cancer"},{"key":"4005_CR4","doi-asserted-by":"publisher","first-page":"4623","DOI":"10.1002\/cncr.26086","volume":"117","author":"B Tran","year":"2011","unstructured":"Tran B, Kopetz S, Tie J et al (2011) Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 117:4623\u20134632. https:\/\/doi.org\/10.1002\/cncr.26086","journal-title":"Cancer"},{"key":"4005_CR5","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.clcc.2014.06.001","volume":"13","author":"V Morris","year":"2014","unstructured":"Morris V, Overman MJ, Jiang Z-Q et al (2014) Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer 13:164\u2013171. https:\/\/doi.org\/10.1016\/j.clcc.2014.06.001","journal-title":"Clin Colorectal Cancer"},{"key":"4005_CR6","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1200\/jco.2015.63.2497","volume":"33","author":"S Kopetz","year":"2015","unstructured":"Kopetz S, Desai J, Chan E et al (2015) Phase II pilot study of vemurafenib in patients with metastatic braf-mutated colorectal cancer. J Clin Oncol 33:4032\u20134038. https:\/\/doi.org\/10.1200\/jco.2015.63.2497","journal-title":"J Clin Oncol"},{"key":"4005_CR7","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1093\/annonc\/mdw645","volume":"28","author":"JF Seligmann","year":"2017","unstructured":"Seligmann JF, Fisher D, Smith CG et al (2017) Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials. Ann Oncol 28:562\u2013568. https:\/\/doi.org\/10.1093\/annonc\/mdw645","journal-title":"Ann Oncol"},{"key":"4005_CR8","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMoa1502309","volume":"373","author":"DM Hyman","year":"2015","unstructured":"Hyman DM, Puzanov I, Subbiah V et al (2015) Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 373:726\u2013736. https:\/\/doi.org\/10.1056\/NEJMoa1502309","journal-title":"N Engl J Med"},{"key":"4005_CR9","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature10868","volume":"483","author":"A Prahallad","year":"2012","unstructured":"Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R (2012) Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483:100\u2013103. https:\/\/doi.org\/10.1038\/nature10868","journal-title":"Nature"},{"key":"4005_CR10","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1158\/2159-8290.Cd-11-0341","volume":"2","author":"RB Corcoran","year":"2012","unstructured":"Corcoran RB, Ebi H, Turke AB et al (2012) EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2:227\u2013235. https:\/\/doi.org\/10.1158\/2159-8290.Cd-11-0341","journal-title":"Cancer Discov"},{"key":"4005_CR11","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1158\/2159-8290.Cd-17-1226","volume":"8","author":"RB Corcoran","year":"2018","unstructured":"Corcoran RB, Andr\u00e9 T, Atreya CE et al (2018) Combined BRAF, EGFR, and MEK inhibition in patients with BRAF(V600E)-mutant colorectal cancer. Cancer Discov 8:428\u2013443. https:\/\/doi.org\/10.1158\/2159-8290.Cd-17-1226","journal-title":"Cancer Discov"},{"key":"4005_CR12","doi-asserted-by":"publisher","DOI":"10.1200\/Jco.20.01994","author":"S Kopetz","year":"2021","unstructured":"Kopetz S, Guthrie KA, Morris VK et al (2021) Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406). J Clin Oncol. https:\/\/doi.org\/10.1200\/Jco.20.01994","journal-title":"J Clin Oncol"},{"key":"4005_CR13","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1158\/2159-8290.CD-16-0050","volume":"6","author":"DS Hong","year":"2016","unstructured":"Hong DS, Morris VK, El Osta B et al (2016) Phase IB study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAFV600E mutation. Cancer Discov 6:1352\u20131365. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0050","journal-title":"Cancer Discov"},{"key":"4005_CR14","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","volume":"381","author":"S Kopetz","year":"2019","unstructured":"Kopetz S, Grothey A, Yaeger R et al (2019) Encorafenib, binimetinib, and cetuximab in BRAF V600E\u2013mutated colorectal cancer. N Engl J Med 381:1632\u20131643. https:\/\/doi.org\/10.1056\/NEJMoa1908075","journal-title":"N Engl J Med"},{"key":"4005_CR15","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1200\/jco.20.02088","volume":"39","author":"J Tabernero","year":"2021","unstructured":"Tabernero J, Grothey A, Van Cutsem E et al (2021) Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study. J Clin Oncol 39:273\u2013284. https:\/\/doi.org\/10.1200\/jco.20.02088","journal-title":"J Clin Oncol"},{"key":"4005_CR16","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1158\/2159-8290.Cd-16-0795","volume":"7","author":"R van Geel","year":"2017","unstructured":"van Geel R, Tabernero J, Elez E et al (2017) A phase Ib dose-escalation study of encorafenib and cetuximab with or without alpelisib in metastatic BRAF-mutant colorectal cancer. Cancer Discov 7:610\u2013619. https:\/\/doi.org\/10.1158\/2159-8290.Cd-16-0795","journal-title":"Cancer Discov"},{"key":"4005_CR17","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/nm.3967","volume":"21","author":"J Guinney","year":"2015","unstructured":"Guinney J, Dienstmann R, Wang X et al (2015) The consensus molecular subtypes of colorectal cancer. Nat Med 21:1350\u20131356. https:\/\/doi.org\/10.1038\/nm.3967","journal-title":"Nat Med"},{"key":"4005_CR18","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/modpathol.2016.95","volume":"29","author":"MW Rosenbaum","year":"2016","unstructured":"Rosenbaum MW, Bledsoe JR, Morales-Oyarvide V, Huynh TG, Mino-Kenudson M (2016) PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. Mod Pathol 29:1104\u20131112. https:\/\/doi.org\/10.1038\/modpathol.2016.95","journal-title":"Mod Pathol"},{"key":"4005_CR19","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.3892\/ol.2020.11647","volume":"20","author":"T Zhao","year":"2020","unstructured":"Zhao T, Li Y, Zhang J, Zhang B (2020) PD-L1 expression increased by IFN-gamma via JAK2-STAT1 signaling and predicts a poor survival in colorectal cancer. Oncol Lett 20:1127\u20131134. https:\/\/doi.org\/10.3892\/ol.2020.11647","journal-title":"Oncol Lett"},{"key":"4005_CR20","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/onco.13741","volume":"26","author":"IH Sahin","year":"2021","unstructured":"Sahin IH, Goyal S, Pumpalova Y et al (2021) Mismatch repair (MMR) gene alteration and BRAF V600E mutation are potential predictive biomarkers of immune checkpoint inhibitors in mmr-deficient colorectal cancer. Oncologist 26:668\u2013675. https:\/\/doi.org\/10.1002\/onco.13741","journal-title":"Oncologist"},{"key":"4005_CR21","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.immuni.2016.01.024","volume":"44","author":"PJR Ebert","year":"2016","unstructured":"Ebert PJR, Cheung J, Yang Y et al (2016) MAP kinase inhibition promotes T Cell and anti-tumor activity in combination with PD-L1 checkpoint blockade. Immunity 44:609\u2013621. https:\/\/doi.org\/10.1016\/j.immuni.2016.01.024","journal-title":"Immunity"},{"key":"4005_CR22","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1158\/2159-8290.CD-20-0873","volume":"11","author":"A Hong","year":"2021","unstructured":"Hong A, Piva M, Liu S et al (2021) Durable suppression of acquired MEK inhibitor resistance in cancer by sequestering MEK from ERK and promoting antitumor T-cell immunity. Cancer Discov 11:714\u2013735. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0873","journal-title":"Cancer Discov"},{"key":"4005_CR23","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1158\/1078-0432.CCR-14-2339","volume":"21","author":"L Liu","year":"2015","unstructured":"Liu L, Mayes PA, Eastman S et al (2015) The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4. Clin Cancer Res 21:1639\u20131651. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2339","journal-title":"Clin Cancer Res"},{"key":"4005_CR24","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1038\/s41591-020-1082-2","volume":"26","author":"R Dummer","year":"2020","unstructured":"Dummer R, Lebbe C, Atkinson V et al (2020) Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. Nat Med 26:1557\u20131563. https:\/\/doi.org\/10.1038\/s41591-020-1082-2","journal-title":"Nat Med"},{"key":"4005_CR25","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/s41591-019-0476-5","volume":"25","author":"A Ribas","year":"2019","unstructured":"Ribas A, Lawrence D, Atkinson V et al (2019) Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. Nat Med 25:936\u2013940. https:\/\/doi.org\/10.1038\/s41591-019-0476-5","journal-title":"Nat Med"},{"key":"4005_CR26","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/s41591-019-0474-7","volume":"25","author":"RJ Sullivan","year":"2019","unstructured":"Sullivan RJ, Hamid O, Gonzalez R et al (2019) Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. Nat Med 25:929\u2013935. https:\/\/doi.org\/10.1038\/s41591-019-0474-7","journal-title":"Nat Med"},{"key":"4005_CR27","doi-asserted-by":"publisher","DOI":"10.3892\/or.2021.8226","author":"E Tak","year":"2022","unstructured":"Tak E, Kim M, Cho Y et al (2022) Expression of neurofibromin 1 in colorectal cancer and cetuximab resistance. Oncol Rep. https:\/\/doi.org\/10.3892\/or.2021.8226","journal-title":"Oncol Rep"},{"key":"4005_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20235899","author":"WU Koh","year":"2019","unstructured":"Koh WU, Kim J, Lee J, Song GW, Hwang GS, Tak E, Song JG (2019) Remote ischemic preconditioning and diazoxide protect from hepatic ischemic reperfusion injury by inhibiting HMGB1-induced TLR4\/MyD88\/NF-kappaB signaling. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms20235899","journal-title":"Int J Mol Sci"},{"key":"4005_CR29","doi-asserted-by":"publisher","first-page":"4231","DOI":"10.3892\/etm.2019.8081","volume":"18","author":"JH Kwon","year":"2019","unstructured":"Kwon JH, Lee J, Kim J et al (2019) HIF-1alpha regulates A2B adenosine receptor expression in liver cancer cells. Exp Ther Med 18:4231\u20134240. https:\/\/doi.org\/10.3892\/etm.2019.8081","journal-title":"Exp Ther Med"},{"key":"4005_CR30","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1177\/0300060516662735","volume":"44","author":"E Tak","year":"2016","unstructured":"Tak E, Park GC, Kim SH, Jun DY, Lee J, Hwang S, Song GW, Lee SG (2016) Epigallocatechin-3-gallate protects against hepatic ischaemia-reperfusion injury by reducing oxidative stress and apoptotic cell death. J Int Med Res 44:1248\u20131262. https:\/\/doi.org\/10.1177\/0300060516662735","journal-title":"J Int Med Res"},{"key":"4005_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/cells9061521","author":"J Lee","year":"2020","unstructured":"Lee J, Choi J, Kang S et al (2020) Hepatogenic potential and liver regeneration effect of human liver-derived mesenchymal-like stem cells. Cells. https:\/\/doi.org\/10.3390\/cells9061521","journal-title":"Cells"},{"key":"4005_CR32","doi-asserted-by":"publisher","first-page":"672","DOI":"10.14348\/molcells.2019.0003","volume":"42","author":"JH Kwon","year":"2019","unstructured":"Kwon JH, Lee J, Kim J et al (2019) Upregulation of carbonyl reductase 1 by Nrf2 as a potential therapeutic intervention for ischemia\/ reperfusion injury during liver transplantation. Mol Cells 42:672\u2013685. https:\/\/doi.org\/10.14348\/molcells.2019.0003","journal-title":"Mol Cells"},{"key":"4005_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.808964","volume":"12","author":"Z Bai","year":"2021","unstructured":"Bai Z, Zhou Y, Ye Z, Xiong J, Lan H, Wang F (2021) Tumor-infiltrating lymphocytes in colorectal cancer: the fundamental indication and application on immunotherapy. Front Immunol 12:808964. https:\/\/doi.org\/10.3389\/fimmu.2021.808964","journal-title":"Front Immunol"},{"key":"4005_CR34","doi-asserted-by":"publisher","first-page":"6483","DOI":"10.1158\/1078-0432.Ccr-17-3384","volume":"24","author":"M Dankner","year":"2018","unstructured":"Dankner M, Lajoie M, Moldoveanu D et al (2018) Dual MAPK inhibition is an effective therapeutic strategy for a subset of class II BRAF mutant melanomas. Clin Cancer Res 24:6483\u20136494. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-3384","journal-title":"Clin Cancer Res"},{"key":"4005_CR35","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1158\/1078-0432.Ccr-12-1630","volume":"19","author":"DT Frederick","year":"2013","unstructured":"Frederick DT, Piris A, Cogdill AP et al (2013) BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 19:1225\u20131231. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-12-1630","journal-title":"Clin Cancer Res"},{"key":"4005_CR36","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1158\/1078-0432.Ccr-12-1626","volume":"19","author":"C Liu","year":"2013","unstructured":"Liu C, Peng W, Xu C et al (2013) BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res 19:393\u2013403. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-12-1626","journal-title":"Clin Cancer Res"},{"key":"4005_CR37","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa4691","author":"S Hu-Lieskovan","year":"2015","unstructured":"Hu-Lieskovan S, Mok S, Moreno BH et al (2015) Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aaa4691","journal-title":"Sci Transl Med"},{"key":"4005_CR38","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1007\/s00262-020-02804-4","volume":"70","author":"L Peiffer","year":"2021","unstructured":"Peiffer L, Farahpour F, Sriram A et al (2021) BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes. Cancer Immunol Immunother 70:1635\u20131647. https:\/\/doi.org\/10.1007\/s00262-020-02804-4","journal-title":"Cancer Immunol Immunother"},{"key":"4005_CR39","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1158\/2326-6066.CIR-13-0215","volume":"2","author":"ZA Cooper","year":"2014","unstructured":"Cooper ZA, Juneja VR, Sage PT et al (2014) Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res 2:643\u2013654. https:\/\/doi.org\/10.1158\/2326-6066.CIR-13-0215","journal-title":"Cancer Immunol Res"},{"key":"4005_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.661737","volume":"12","author":"EJ Lelliott","year":"2021","unstructured":"Lelliott EJ, McArthur GA, Oliaro J, Sheppard KE (2021) Immunomodulatory effects of BRAF, MEK, and CDK4\/6 inhibitors: implications for combining targeted therapy and immune checkpoint blockade for the treatment of melanoma. Front Immunol 12:661737. https:\/\/doi.org\/10.3389\/fimmu.2021.661737","journal-title":"Front Immunol"},{"key":"4005_CR41","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12918-017-0446-9","volume":"11","author":"X Lai","year":"2017","unstructured":"Lai X, Friedman A (2017) Combination therapy for melanoma with BRAF\/MEK inhibitor and immune checkpoint inhibitor: a mathematical model. BMC Syst Biol 11:70. https:\/\/doi.org\/10.1186\/s12918-017-0446-9","journal-title":"BMC Syst Biol"},{"key":"4005_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14225489","author":"M Welti","year":"2022","unstructured":"Welti M, Dimitriou F, Gutzmer R, Dummer R (2022) Triple combination of immune checkpoint inhibitors and BRAF\/MEK inhibitors in BRAFV600 melanoma: current status and future perspectives. Cancers. https:\/\/doi.org\/10.3390\/cancers14225489","journal-title":"Cancers"},{"key":"4005_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.693655","volume":"11","author":"Y Liu","year":"2021","unstructured":"Liu Y, Zhang X, Wang G, Cui X (2021) Triple combination therapy With PD-1\/PD-L1, BRAF, and MEK inhibitor for stage III-IV melanoma: a systematic review and meta-analysis. Front Oncol 11:693655. https:\/\/doi.org\/10.3389\/fonc.2021.693655","journal-title":"Front Oncol"},{"key":"4005_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.705060","author":"S Cen","year":"2021","unstructured":"Cen S, Liu K, Zheng Y, Shan J, Jing C, Gao J, Pan H, Bai Z, Liu Z (2021) BRAF mutation as a potential therapeutic target for checkpoint inhibitors: a comprehensive analysis of immune microenvironment in BRAF mutated colon cancer. Front Cell Dev Biol. https:\/\/doi.org\/10.3389\/fcell.2021.705060","journal-title":"Front Cell Dev Biol"},{"key":"4005_CR45","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.3390\/cancers14102383","volume":"14","author":"JE Kim","year":"2022","unstructured":"Kim JE, Kim J-H, Kim S-Y, Cho H, Ryu Y-M, Hong YS, Kim SY, Kim TW (2022) Immune profile of BRAF-mutated metastatic colorectal tumors with good prognosis after palliative chemotherapy. Cancers 14:2383","journal-title":"Cancers"},{"key":"4005_CR46","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41591-022-02181-8","volume":"29","author":"J Tian","year":"2023","unstructured":"Tian J, Chen JH, Chao SX et al (2023) Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial. Nat Med 29:458\u2013466. https:\/\/doi.org\/10.1038\/s41591-022-02181-8","journal-title":"Nat Med"}],"updated-by":[{"DOI":"10.1007\/s00262-025-04056-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000}}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04005-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04005-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04005-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T09:09:32Z","timestamp":1745917772000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04005-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":46,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["4005"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04005-3","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00262-025-04056-6","asserted-by":"object"}]},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]},"assertion":[{"value":"11 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00262-025-04056-6","URL":"https:\/\/doi.org\/10.1007\/s00262-025-04056-6","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Institutional Animal Care and Use Committee (IACUC) at Asan Medical Center (AMC) (Approval number 2021\u201312-022).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"154"}}